A multicentric observational study aiming to evaluate renal outcomes associated with canagliflozin in Patients with Type 2 Diabetes Mellitus
Latest Information Update: 30 Aug 2024
Price :
$35 *
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms INTENSIFY
- 30 Aug 2024 New trial record